Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl E Orringer

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Trends in Cardiovascular Medicine|May 19, 2019
Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?Carl E Orringer
European Heart Journal|March 17, 2023
C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander?Carl E Orringer
Journal of Clinical Lipidology|December 3, 2010
The absence of coronary calcium: clinical and therapeutic implications for the clinical lipidologistCarl E Orringer
Methodist Debakey Cardiovascular Journal|May 4, 2019
How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)linesCarl E Orringer
European Heart Journal|October 25, 2021
PCSK9 inhibition for acute arterial events: more than LDL loweringCarl E Orringer
Journal of the American College of Cardiology|May 22, 2024
Over-the-Counter Statins: Revisited After a GenerationCarl E Orringer
Journal of Clinical Lipidology|May 22, 2016
Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease preventionCarl E Orringer, Pamela B Morris
Mayo Clinic Proceedings|July 11, 2020
HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 WordsCarl E Orringer, Kevin C Maki
Mayo Clinic Proceedings|January 8, 2021
In Reply-Coronary Artery Calcium Scores I and IICarl E Orringer, Kevin C Maki
Current Atherosclerosis Reports|November 16, 2023
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering TherapyJelani K Grant, Carl E Orringer
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Trends in Cardiovascular Medicine|May 19, 2019
Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?Carl E Orringer
European Heart Journal|March 17, 2023
C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander?Carl E Orringer
Journal of Clinical Lipidology|December 3, 2010
The absence of coronary calcium: clinical and therapeutic implications for the clinical lipidologistCarl E Orringer
Methodist Debakey Cardiovascular Journal|May 4, 2019
How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)linesCarl E Orringer
European Heart Journal|October 25, 2021
PCSK9 inhibition for acute arterial events: more than LDL loweringCarl E Orringer
Journal of the American College of Cardiology|May 22, 2024
Over-the-Counter Statins: Revisited After a GenerationCarl E Orringer
Journal of Clinical Lipidology|May 22, 2016
Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease preventionCarl E Orringer, Pamela B Morris
Mayo Clinic Proceedings|July 11, 2020
HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 WordsCarl E Orringer, Kevin C Maki
Mayo Clinic Proceedings|January 8, 2021
In Reply-Coronary Artery Calcium Scores I and IICarl E Orringer, Kevin C Maki
Current Atherosclerosis Reports|November 16, 2023
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering TherapyJelani K Grant, Carl E Orringer
Pageof 6